Cory Mavis相关文献与解析，生知库 | 链接生命科学的每一步

Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma

二甲双胍可增强治疗药物的敏感性并改善临床前和临床弥漫大 B 细胞淋巴瘤的预后

Anil R Singh #, Juan J Gu #, Qunling Zhang, Pallawi Torka, Suchitra Sundaram, Cory Mavis, Francisco J Hernandez-Ilizaliturri

肿瘤

Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma

Pevonedistat 是一种 NEDD8 活化酶抑制剂，可诱导细胞凋亡并增强弥漫性大 B 细胞淋巴瘤临床前模型中化疗和小分子抑制剂的疗效

期刊:eJHaem

影响因子:

doi:10.1002/jha2.2

Pallawi Torka, Cory Mavis, Shalin Kothari, Sarah Belliotti, Juan Gu, Suchitra Sundaram, Matthew Barth, Francisco J Hernandez-Ilizaliturri

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma

针对伯基特淋巴瘤的 PI3K/Akt/mTOR 通路的临床前活性

期刊:Oncotarget

影响因子:

doi:10.18632/oncotarget.25072

Maria Bhatti, Thomas Ippolito, Cory Mavis, Juan Gu, Mitchell S Cairo, Megan S Lim, Francisco Hernandez-Ilizaliturri, Matthew J Barth

Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development

己糖激酶 II 的上调导致利妥昔单抗化疗耐药，是治疗开发的临床相关靶点

期刊:Oncotarget

影响因子:

doi:10.18632/oncotarget.23425

Juan J Gu, Anil Singh, Kai Xue, Cory Mavis, Matthew Barth, Vivek Yanamadala, Peter Lenz, Michael Grau, Georg Lenz, Myron S Czuczman, Francisco J Hernandez-Ilizaliturri

信号转导

发表日期：2017

文献求助收藏

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

Pevonedistat 是一种 NEDD8 活化酶抑制剂，可有效治疗套细胞淋巴瘤并增强利妥昔单抗的体内活性

期刊:Blood

影响因子:21

doi:10.1182/blood-2015-04-640920

Natalie M Czuczman, Matthew J Barth, Juan Gu, Vishala Neppalli, Cory Mavis, Sarah E Frys, Qiang Hu, Song Liu, Pavel Klener, Petra Vockova, Myron S Czuczman, Francisco J Hernandez-Ilizaliturri

Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents

Entinostat 是一种新型组蛋白去乙酰化酶抑制剂，可有效治疗 B 细胞淋巴瘤，并增强利妥昔单抗和化疗药物的抗肿瘤活性

期刊:British Journal of Haematology

影响因子:5.1

doi:10.1111/bjh.13318

Sarah Frys, Zachary Simons, Qiang Hu, Matthew J Barth, Juan J Gu, Cory Mavis, Joseph Skitzki, Liu Song, Myron S Czuczman, Francisco J Hernandez-Ilizaliturri

Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents

阿糖胞苷耐药套细胞淋巴瘤细胞中脱氧胞苷激酶的下调导致对核苷类似物吉西他滨、氟达拉滨和克拉屈滨产生交叉耐药性，但对其他类别的抗淋巴瘤药物无交叉耐药性

期刊:Molecular Cancer

影响因子:27.7

doi:10.1186/1476-4598-13-159

Magdalena Klanova, Lucie Lorkova, Ondrej Vit, Bokang Maswabi, Jan Molinsky, Jana Pospisilova, Petra Vockova, Cory Mavis, Lucie Lateckova, Vojtech Kulvait, Dana Vejmelkova, Radek Jaksa, Francisco Hernandez, Marek Trneny, Martin Vokurka, Jiri Petrak, Pavel Klener Jr

AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas

AMG176 是一种 MCL-1 抑制剂，在侵袭性 B 细胞淋巴瘤的临床前模型中有效

Metformin sensitizes therapeutic agents and improves outcome in pre-clinical and clinical diffuse large B-cell lymphoma

二甲双胍可增强治疗药物的敏感性并改善临床前和临床弥漫大 B 细胞淋巴瘤的预后

Pevonedistat, a NEDD8-Activating Enzyme Inhibitor, Induces Apoptosis and Augments Efficacy of Chemotherapy and Small Molecule Inhibitors in Pre-clinical Models of Diffuse Large B-cell Lymphoma

Pevonedistat 是一种 NEDD8 活化酶抑制剂，可诱导细胞凋亡并增强弥漫性大 B 细胞淋巴瘤临床前模型中化疗和小分子抑制剂的疗效

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma

针对伯基特淋巴瘤的 PI3K/Akt/mTOR 通路的临床前活性

Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development

己糖激酶 II 的上调导致利妥昔单抗化疗耐药，是治疗开发的临床相关靶点

Pevonedistat, a NEDD8-activating enzyme inhibitor, is active in mantle cell lymphoma and enhances rituximab activity in vivo

Pevonedistat 是一种 NEDD8 活化酶抑制剂，可有效治疗套细胞淋巴瘤并增强利妥昔单抗的体内活性

Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents

Entinostat 是一种新型组蛋白去乙酰化酶抑制剂，可有效治疗 B 细胞淋巴瘤，并增强利妥昔单抗和化疗药物的抗肿瘤活性

Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents

阿糖胞苷耐药套细胞淋巴瘤细胞中脱氧胞苷激酶的下调导致对核苷类似物吉西他滨、氟达拉滨和克拉屈滨产生交叉耐药性，但对其他类别的抗淋巴瘤药物无交叉耐药性